Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

Lung cancer accounts for the majority of cancer-related deaths worldwide. At present, platinum-based therapy represents the standard of care in fit stage II and IIIA non-small cell lung cancer (NSCLC) patients following surgical resection. In advanced disease, personalized chemotherapy and targeted...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Transl Lung Cancer Res
Главные авторы: Massuti, Bartomeu, Sanchez, Jose Miguel, Hernando-Trancho, Florentino, Karachaliou, Niki, Rosell, Rafael
Формат: Artigo
Язык:Inglês
Опубликовано: Pioneer Bioscience Publishing Company 2013
Предметы:
Review Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367596/
https://ncbi.nlm.nih.gov/pubmed/25806234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2013.03.06
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы